---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-051729"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T02:11:52.788953+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Chairman Dr. Given to retire; Sarepta CEO Ingram expected to join board

## Summary
- Dr. Douglass Given retires from Board effective Dec 31, 2024, after 14 years as Chairman.
- Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join Board in Q1 2025.
- Ingram's appointment aligns with closing of Arrowhead-Sarepta Exclusive License and Collaboration Agreement (Nov 25, 2024).
- Company expresses gratitude for Dr. Given's service.

## SEC filing metadata
- accession: 0001628280-24-051729
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828024051729/0001628280-24-051729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828024051729/arwr-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-051729
- JSON: https://secwatch.observer/filing/0001628280-24-051729.json
- Plain text: https://secwatch.observer/filing/0001628280-24-051729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.